Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.78 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.74 |
| ▸ | HTR1A | P08908 | 3/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.68 |
| ▸ | ACHE | P22303 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19391015 | 0.87 | SIGMAR1 (0.76) | SIGMAR1HRH3HTR1ASLC6A4 | |
| SCHEMBL12013920 | 0.85 | SIGMAR1 (0.70) | SIGMAR1ACHE | |
| SCHEMBL10669091 | 0.85 | HRH3 (1.00) | SIGMAR1HRH3HTR1ASLC6A4 | |
| SCHEMBL17297879 | 0.85 | SIGMAR1 (0.72) | SIGMAR1HRH3HTR1ASLC6A4 | |
| SCHEMBL18744300 | 0.85 | SIGMAR1 (0.72) | SIGMAR1HRH3HTR1ASLC6A4 | |
| SCHEMBL17294993 | 0.84 | HRH3 (0.97) | SIGMAR1HRH3HTR1ASLC6A4 | |
| SCHEMBL2089103 | 0.82 | SIGMAR1 (0.82) | SIGMAR1HRH3HTR1ASLC6A4 | |
| SCHEMBL12023880 | 0.82 | SIGMAR1 (0.75) | SIGMAR1HRH3HTR1ASLC6A4ACHE | |
| SCHEMBL9387835 | 0.81 | SIGMAR1 (0.85) | SIGMAR1HRH3HTR1ASLC6A4 | |
| SCHEMBL11379089 | 0.81 | SIGMAR1 (0.80) | SIGMAR1HRH3HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776996-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-10-03 | — | — | US | disclosed |
| EP-3022184-B1 | SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20170217941-A1 | SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-08-03 | — | — | US | disclosed |
| US-9701666-B2 | 1,4-pyridone bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-07-11 | — | — | US | disclosed |
| US-9624205-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| EP-3042900-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | Fujifilm Corporation (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20160194316-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2016-07-07 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160152604-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2016-06-02 | — | — | US | disclosed |
| US-20160031907-A1 | Substituted Benzene Compounds | Epizyme, Inc. | 2016-02-04 | — | — | US | disclosed |
| US-20160024081-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. | 2016-01-28 | — | — | US | disclosed |
| US-20150344459-A1 | 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344459-A1 | 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS | CYP4B1, PDXK, CYP1B1 | SIGMAR1 1028/4885HRH3 973/4885HTR1A 229/4885 |
| US-20160024081-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | CYP3A5, PAICS, CYP4B1 | SIGMAR1 1203/4885HRH3 1577/4885HTR1A 2888/4885 |
| US-20160031907-A1 | Substituted Benzene Compounds | CYP1B1, CYP4B1, CYP2B6 | SIGMAR1 3316/4885HRH3 1541/4885HTR1A 1724/4885 |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | PRMT7, RBBP7, RER1 | SIGMAR1 427/4885HRH3 232/4885HTR1A 2691/4885 |
| US-20160152604-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP3A5, PAICS | SIGMAR1 447/4885HRH3 1183/4885HTR1A 1327/4885 |
| US-20170217941-A1 | SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | BCOR, CYP2B6, AHR | SIGMAR1 1355/4885HRH3 709/4885HTR1A 1535/4885 |
| US-20160194316-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | SIGMAR1 2168/4885HRH3 1485/4885HTR1A 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.